Assyov Yavor S, Velikova Tsvetelina V, Kamenov Zdravko A
a Clinic of Endocrinology , University Hospital "Alexandrovska", Medical University , Sofia , Bulgaria.
b Laboratory of Clinical Immunology , University Hospital "St. Ivan Rilski", Medical University , Sofia , Bulgaria.
Endocr Res. 2017 May;42(2):102-109. doi: 10.1080/07435800.2016.1198802. Epub 2016 Jun 29.
Purpose/aim of the study: Myostatin is a myokine that has been shown to inhibit muscle growth and to have potentially deleterious effects on metabolism. The aim of the current study was to compare its circulating serum levels in subjects from the whole spectrum of carbohydrate disturbances leading to diabetes.
A total of 159 age-, sex-, and BMI-matched subjects participated in the study - 50 had normal glucose tolerance (NGT), 60 had prediabetes (PreDM), and 49 had type 2 diabetes mellitus (T2D). Oral glucose tolerance testing was used to determine glucose tolerance. Serum myostatin was quantified by means of ELISA.
Circulating serum myostatin levels were highest in patients with T2D, lower in subjects with prediabetes, and lowest in subjects with normoglycemia (all p < 0.05). Myostatin was shown to be positively associated with fasting plasma glucose, HOMA-IR, hepatic enzymes, uric acid, and FINDRISC questionnaire scores in both sexes. ROC analyses determined circulating myostatin levels to be of value for differentiating subjects with T2D (AUC = 0.72, p = 0.002 in men; AUC = 0.70, p = 0.004 in women) in the study population. After adjustment for potential confounders, in a multiple binary logistic regression model, serum myostatin added further information to traditional risk estimates in distinguishing subjects with T2D.
Serum myostatin levels are higher with deterioration of carbohydrate tolerance. Furthermore, circulating myostatin is positively associated with traditional biochemical estimates of poor metabolic health. These data add to evidence of the involvement of this myokine in the pathogenesis of T2D.
研究目的：肌肉生长抑制素是一种肌动蛋白，已被证明可抑制肌肉生长，并对新陈代谢有潜在的有害影响。本研究的目的是比较处于导致糖尿病的整个碳水化合物紊乱范围内的受试者的循环血清水平。
共有159名年龄、性别和BMI匹配的受试者参与了该研究——50名葡萄糖耐量正常（NGT），60名患有糖尿病前期（PreDM），49名患有2型糖尿病（T2D）。采用口服葡萄糖耐量试验来确定葡萄糖耐量。通过酶联免疫吸附测定法对血清肌肉生长抑制素进行定量。
T2D患者的循环血清肌肉生长抑制素水平最高，糖尿病前期受试者较低，血糖正常受试者最低（所有p<0.05）。在男女两性中，肌肉生长抑制素均与空腹血糖、稳态模型评估胰岛素抵抗（HOMA-IR）、肝酶、尿酸和芬兰糖尿病风险评分问卷得分呈正相关。ROC分析确定循环肌肉生长抑制素水平对区分研究人群中的T2D受试者有价值（男性AUC = 0.72，p = 0.002；女性AUC = 0.70，p = 0.004）。在对潜在混杂因素进行调整后，如果建立一个多元二元逻辑回归模型，血清肌肉生长抑制素在区分T2D受试者时，会为传统风险评估增加更多信息。
血清肌肉生长抑制素水平随着碳水化合物耐量的恶化而升高。此外，循环肌肉生长抑制素与代谢健康不良的传统生化指标呈正相关。这些数据进一步证明了这种肌动蛋白参与了T2D的发病机制。
